Aromatic Amino Acid Decarboxylation Inhibitor

DOPA Decarboxylase Inhibitors

Aromatic Amino Acid

Parkinson Disease

<section class="Section" data-sectioncode="34089-3"><a name="LINK_1319ab86-80c0-4a48-b208-1740f6f9ea66"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">RYTARY is a combination of carbidopa, an inhibitor of aromatic amino acid decarboxylation, and levodopa, an aromatic amino acid, in extended-release capsules for oral use.</p><p>Carbidopa is a white, crystalline compound, slightly soluble in water, with a molecular weight of 244.3. It is designated chemically as (–)-L-α-hydrazino-α-methyl-β-(3,4-dihydroxy-benzene) propanoic acid monohydrate. Its molecular formula is C<span class="Sub">10</span>H<span class="Sub">14</span>N<span class="Sub">2</span>O<span class="Sub">4</span>∙H<span class="Sub">2</span>O and its structural formula is:</p><div class="Figure"><img alt="Chemical Structure 1" src="rytary-extended-release-capsules-1.jpg"/></div><p>Capsule content is expressed in terms of anhydrous carbidopa, which has a molecular weight of 226.3.</p><p>Levodopa is a white, crystalline compound, slightly soluble in water, with a molecular weight of 197.2. It is designated chemically as (–)-L-α-amino-β-(3,4-dihydroxybenzene) propanoic acid. Its molecular formula is C<span class="Sub">9</span>H<span class="Sub">11</span>NO<span class="Sub">4</span> and its structural formula is:</p><div class="Figure"><img alt="Chemical Structure 2" src="rytary-extended-release-capsules-2.jpg"/></div><p>Each extended-release capsule contains 23.75 mg carbidopa and 95 mg levodopa, 36.25 mg carbidopa and 145 mg levodopa, 48.75 mg carbidopa and 195 mg levodopa, or 61.25 mg carbidopa and 245 mg levodopa. The inactive ingredients are microcrystalline cellulose, mannitol, tartaric acid, ethyl cellulose, hypromellose, sodium starch glycolate, sodium lauryl sulfate, povidone, talc, methacrylic acid copolymers, triethyl citrate, croscarmellose sodium, and magnesium stearate. </p><p>The capsule shells all contain gelatin and titanium dioxide. All blue capsule components contain FD&amp;C Blue #2 and yellow iron oxide. All yellow capsule components contain yellow iron oxide. All capsules with black imprinting contain iron oxide black. All capsules with blue imprinting contain FD&amp;C Blue #2.</p></section>

RYTARY

carbidopa / levodopa

Rytary

8 HR carbidopa 23.75 MG / levodopa 95 MG Extended Release Oral Capsule

8 HR carbidopa 23.75 MG / levodopa 95 MG Extended Release Oral Capsule [Rytary]

8 HR carbidopa 36.25 MG / levodopa 145 MG Extended Release Oral Capsule

8 HR carbidopa 36.25 MG / levodopa 145 MG Extended Release Oral Capsule [Rytary]

8 HR carbidopa 48.75 MG / levodopa 195 MG Extended Release Oral Capsule

8 HR carbidopa 48.75 MG / levodopa 195 MG Extended Release Oral Capsule [Rytary]

8 HR carbidopa 61.25 MG / levodopa 245 MG Extended Release Oral Capsule

8 HR carbidopa 61.25 MG / levodopa 245 MG Extended Release Oral Capsule [Rytary]

carbidopa

levodopa

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Pharmacy List 

Reimbursement Information (Request a Rep Pop-Up)

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Letter of Medical Necessity - Step Therapy

Letter of Medical Necessity - Motor Fluctuations 

Enroll in Patient Savings Program 

Amneal Patient Assistance Program Application 

Rytary HCP Portal 

Other HCP Resources 

Other HCP Resources: Videos 

About Rytary 

Patient Stories 

MyRytary Support Program 

Instructions For Use: Parkinson's Disease 

Rytary Start Guide 

Rytary Start Guide - Spanish

Patient Brochure 

Patient Brohcure - Spanish

Treatment Journal 

Treatment Journal - Spanish 

Treatment Tracker 

Treatment Tracker - Spanish